Latest Breaking News On - Wildon farwell - Page 2 : comparemela.com

Dyne Therapeutics (NASDAQ:DYN) Receives Outperform Rating from Oppenheimer

Dyne Therapeutics (NASDAQ:DYN) Receives Outperform Rating from Oppenheimer
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United statesJasonp rhodesWildon farwellStifel nicolausPiper sandlerDyne therapeutics company profileVivo capitalFcpm iii servicesDyne therapeutics incMorgan stanleyJennison associatesArmistice capitalSecurities exchange commissionDyne therapeuticsFree reportChardan capital

Oppenheimer Reaffirms Outperform Rating for Dyne Therapeutics (NASDAQ:DYN)

Oppenheimer Reaffirms Outperform Rating for Dyne Therapeutics (NASDAQ:DYN)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesWildon farwellPiper sandlerStifel nicolausSwiss national bankDyne therapeutics incMorgan stanleySei investments coVenture fund xilp atlasSecurities exchange commissionInvestment advisorsRussell investments group ltdProshare advisorsDyne therapeuticsFree reportModerate buy

Dyne Therapeutics (NASDAQ:DYN) Stock Rating Reaffirmed by Chardan Capital

Dyne Therapeutics (NASDAQ:DYN) Stock Rating Reaffirmed by Chardan Capital
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesJoshuat brummPiper sandlerZurcher kantonalbank zurich cantonalbankStifel nicolausWildon farwellWetzel investment advisors incMorgan stanleyChina universal asset management coDyne therapeutics incAllspring global investments holdingsSg americas securitiesChardan capitalDyne therapeuticsFree reportDyne therapeutic

HC Wainwright Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $36.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 38.04% from the company’s […]

United statesPiper sandlerStifel nicolausJasonp rhodesWildon farwellZurcher kantonalbank zurich cantonalbankAllspring global investments holdingsWetzel investment advisors incSg americas securitiesChina universal asset management coDyne therapeutics incSecurities exchange commissionMorgan stanleyDyne therapeuticsGet free reportChardan capital

Morgan Stanley Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)

Morgan Stanley started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report released on Tuesday, Briefing.com reports. The firm set an “overweight” rating and a $40.00 price target on the stock. Morgan Stanley’s price target indicates a potential upside of 57.11% from the company’s previous close. A number of other […]

United statesStifel nicolausJoshuat brummRaymond jamesWildon farwellZurcher kantonalbank zurich cantonalbankRaymond james associatesYork mellon corpDyne therapeutics incMorgan stanleySecurities exchange commissionAllspring global investments holdingsTd asset management incDyne therapeuticsGet free reportExchange commission